SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sada JR, Hersh EM, Manning J et al. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood 1986; 68: 4937.
  • 2
    Talpaz M, Kantarjian HM, McCredie KB, Keatmg MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 12808.
  • 3
    Gisslinger H, Ltidwig H, Fritz E, Linkesch W, Chott A, Radasz-kiewlcz TH. Long-term interferon therapy for thrombocytosis in myeloproliferative diseases. Lancet 1989; i: 6347.
  • 4
    Davis GL, Balart LA, Schiff ER et al. Treatment of chronic hepatitis C wilh recombinant intcrferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15016.
  • 5
    Qucsada JR, Talpaz M, Rios A, Kurzrock R, Gutterman J. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986; 4: 23443.
  • 6
    Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H. Treatment of essential ihrombocythaemia with inlerferon alpha. Brit J Haemafol (Suppl. 1) 1991; 79: 4247.
  • 7
    Burman P, Töttermann TH, Oberg K, Karlsson FA. Thyroid autoimmunity in patients on long term therapy wilh leukocyte-derived interferon. J Clin Endocrinol Metab 1986; 63: 108690.
  • 8
    Fenliman IS, Balkwin FR, Thomas BS, Russeau MJ, Todd I, Boltazzo GF. An autoimmune aetiology for hypothyroidism following interferon iherapy for breasl cancer. Eur J C ancer Clin Oncol 1988; 24: 1299303.
  • 9
    Ronnblom LE, Aim GV, Oberg KF. Autoimmunity after alpha intcrferon therapy for malignant carcinoid lutiiors. Ann Intern Med 1991; 115: 17883.
  • 10
    Mayet WJ, Hess G, Gerken G, RossoI S, Voth R, Manns M, Meyer zum Buschenfelde KH. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepalitis. Hepalology 1989; 10: 2428.
  • 11
    Conlon KC, Urba WJ, Smith JW, Steis RG, Longo DL, Clark JW. Exacerbation of sytiiptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990; 65: 223742.
  • 12
    Gisslinger H, Chotl A, Linkesch W, Frilz E, Ludwig H. Long-term aifa-inlerferon therapy in myelodysplastic syndromes. Leukemia 1990; 4: 9194.
  • 13
    Gisslinger H, Gilly B, Weissel M. Occurrence of thyroid autoimmu-nily in patients on long-term treatment with recombinani interferon alpha. Ann Endocrinol 1989; 50: 160 (abstract).
  • 14
    Beever K, Brandbury J, Phillips D et al. Highly sensitive assays of autoantibodies lo thyroglobulin and to thyroid peroxidase. Clin Chem 1989; 35: 194954.
  • 15
    Marcadet A, O'Connell P, Cohen D. Standard ized Southern blot workshop technique. In: DupontB. ed. Immunobiology of HLA. Vol. 1. Histocompatibility testing 1987. New York : Springer Verlag 1989; 55360.
  • 16
    Weissel M, Höfer R, Zasmeta H, Mayr WR. HLA-DR and Hashimoto's Thyroiditis. Tisstie Antigens 1980; 16: 2567.
  • 17
    Tandon N, Zhang L, Weetman AP. HLA associations with Hashimoto's thyroiditis. Clin Endocrinol 1991; 34: 3836.
  • 18
    Phillips D, Prentice L, Upadhyaya M et al. Autosomal—dominant inheritance ofautoanti bodies to thyroid peroxidase and thyroglobulin—studies in families not selected forautoinimtine thyroid disease. J Clin Endocrinol Metab 1991; 72: 9735.
  • 19
    Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic, syndronies. I. Serum immunoglobulins and autoantibodies. Brit J Haematol 1986; 63: 1437.
  • 20
    D'Urso R, Falaschi P, Canfalone G, Carusi B et al. Neuroendocrine effects of recombinant alpha-interferon administration in humans. Prog NeuroEndocrinlmmunol 1991;4: 2025.
  • 21
    Daniels HM, Meager A, Eddlestom ALWF, Alexander GJM, Wilhatiis R. Spontaneous production of tumour neerosis factor alpha and interleukin-1 beta during interferon-alpha treatment of chronic HBV infection. Lancet 1990; 335: 8757.
  • 22
    Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment wilh interleukin-2 and lymphokine activated killer cells. N Engl J Med 1988; 318: 155763.
  • 23
    Van Liessum PA, De Muldner PHM, Mattijssen EJM, Corstens FHM, Wagener DJTH. Hypothyroidism and goitre during inter-leukin-2 therapy without LAK cells. Lancet 1989; i: 224.
  • 24
    Hoekman K, Blomberg-vander Flier BM, Wagstalf J, Drexhage HA, Pinedo HM. Reversible thyroid dysfunction during treatment wilh GM-CSF. Lancel 1991; 338: 5412.
  • 25
    Lucas-Marlin A, Foz-Sala M, Todd I, Bottazzo F, Pujol Borrell R. Occurrenceof thyrocyte HLA class II expression in a wide variety of ihyroid diseases: relationship with lymphocytic infiltration and thyroid autoantibodies. J Clin Endocrinol Metab 1988; 66: 36775.
  • 26
    Todd I, McNally JM, Hammond LJ, Ptijol-Borreil R. TSH enhances expression by thyrocytcsofinterferon-gamma indueed HLA-D/DR. In: Medeiros-NeloG, GaitanE, eds. Frontiers in thyroidology. New York : Plenum Press, 1986; 15514.
  • 27
    Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. J Exp Med 1984; 160: 31016.